Overview

* Minerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024

* Company's Q3 operating expenses decreased due to lower R&D and G&A costs

* Minerva secures $80 mln in financing for Phase 3 trial of roluperidone

Outlook

* Minerva anticipates increased R&D and administrative expenses for Phase 3 trial and NDA resubmission

* Company expects to have sufficient funds for Phase 3 study and potential US launch

Result Drivers

* FINANCING - Minerva received $80 mln in private placement to fund Phase 3 trial of roluperidone

* LOWER R&D EXPENSES - R&D expenses decreased due to lower costs for drug substance validation and consultant fees

* LOWER G&A EXPENSES - G&A expenses fell due to reduced professional service fees and insurance costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.36

Q3 Net -$2.74

Income mln

Q3 -$2.84

Income mln

from

Operatio

ns

Q3 $2.84

Operatin mln

g

Expenses

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)